Hook / Thesis
Arvinas (ARVN) sits at the inflection point for a new drug class: PROTAC protein degraders. The company just saw VEPPANU (vepdegestrant) win FDA approval for ESR1-mutated ER+/HER2- advanced breast cancer, and it reported encouraging Phase 1 pharmacodynamic data for ARV-102, a LRRK2 degrader targeting Parkinson's disease biology. At a market capitalization of ~$456.8M and an enterprise value of ~$363.4M, the stock appears priced for significant execution risk but not for a successful commercial launch plus a progressing neurology program. That combination is the basis for a Monte Rosa initiation - Buy.
Why the market should care
VEPPANU represents the first approved PROTAC therapy - a class designed to eliminate disease-causing proteins rather than just inhibit them. FDA approval of VEPPANU (05/01/2026) and the companion diagnostic approval for Guardant360 CDx remove two of the biggest technical and diagnostic gating items for commercialization. Separately, ARV-102 showed >50% LRRK2 degradation in Phase 1 and is positioned to enter Phase 1b/Phase 2 registrational plans in progressive supranuclear palsy in the second half of 2026. That gives Arvinas a two-pronged value path: a near-term commercial story and a mid-term neurology pipeline de-risking event set.
Business snapshot
Arvinas is a biopharma company advancing targeted protein degraders. The company has an approved product - VEPPANU - developed with Pfizer and is advancing multiple pipeline candidates including ARV-102 (LRRK2 degrader) and ER-targeting degraders like ARV-471/766. Key corporate figures: market cap ~$456,810,112, shares outstanding ~64.52M, float ~54.46M, and a current stock price around $7.09. The balance sheet shows cash on hand roughly $48M (cash per share reported at $0.75), no recorded debt, and a negative free cash flow of approximately -$256.9M, indicating ongoing R&D and launch investment needs.
Valuation framing
At today's price the company trades with a price-to-sales of ~5.04 and EV/sales ~4.06. Back-of-envelope math using the provided multiples implies trailing revenues are on the order of ~$90M (market cap / P/S), though those revenues are likely early and will be materially revised as commercial roll-out proceeds. Market cap of ~$457M values a company that now has at least one approved product and a progressing neurology program - a discount compared with peers that have commercial franchises and later-stage pipelines. The discount reflects real execution risk: partner selection for commercialization, payer coverage, and cash burn through launch. If Arvinas secures a commercialization partner that brings salesforce and distribution scale, or if early revenue print beats expectations, the multiple could re-rate toward typical small-cap commercialized biotech levels.
Technical context
The technical picture shows the stock is oversold on momentum indicators - 9-day EMA sits above current price and RSI is low at ~24, signaling depressed sentiment. Short interest has been meaningful historically (most recent settle ~4.7M shares, days to cover ~5.88), indicating both skepticism and potential for squeezes around positive catalysts.
Trade plan (actionable)
Setup: Buy ARVN at $7.09 (current price) with a disciplined stop and two-stage target strategy. Time horizon: long term (180 trading days) to allow for initial launch signals and ARV-102 development updates. I outline how the position should be managed across shorter windows below.
- Entry: $7.09
- Stop loss: $5.50 (protects capital if commercial or safety headlines drive a re-rate; represents a downside that preserves optionality without waiting for full washouts)
- Target: $13.50 (near-term upside tied to successful commercialization partner selection, early launch revenue beats, or strong ARV-102 Phase 1b/2 signals)
Horizon and trade cadence
Short term (10 trading days) - watch for immediate post-earnings or partner selection news and intraday liquidity. I would treat any sharp pop on partnership news as an opportunity to trim into strength and lock partial gains.
Mid term (45 trading days) - anticipate initial market reactions to commercialization partner announcements, distribution plans, and early launch feedback (prescriber interest, diagnostic uptake). Re-evaluate position sizing if revenue guidance or partner terms become public.
Long term (180 trading days) - this is the primary horizon for this trade. Allow time for commercial execution to begin showing in revenue prints and for ARV-102 to move into its next clinical stage. The target of $13.50 anticipates successful commercialization planning plus meaningful pipeline progress being priced in.
Supporting facts and numbers
| Metric | Value |
|---|---|
| Market cap | $456,810,112 |
| Enterprise value | $363,357,962 |
| Shares outstanding | 64,521,202 |
| Price-to-sales | 5.04 |
| EV-to-sales | 4.06 |
| Cash (approx) | $48M |
| Free cash flow (trailing) | -$256.9M |
Catalysts to watch
- Commercialization partner announcement and terms - partner selection could materially reduce execution risk and support faster uptake.
- First commercial revenue prints or launch metrics (script counts, diagnostic uptake) after launch - early uptake would validate the market opportunity.
- Regulatory or payer news on coverage and reimbursement for VEPPANU and Guardant360 CDx adoption.
- ARV-102 development updates - start of Phase 1b or Phase 2 registrational discussions in H2 2026.
- Quarterly financials and guidance that clarify cash burn and potential need for financing (any financing terms will move the valuation).
Risks and counterarguments
Below are the principal downside scenarios and alternative views that argue against the trade thesis.
- Commercial execution and partner risk - VEPPANU approval is necessary but not sufficient. Arvinas plans to select a third-party commercialization partner; unfavorable economics or long timelines to finalize a partner could delay revenue and force the company to self-commercialize, which would increase cash burn.
- Payer and diagnostic uptake - the label targets ESR1-mutated patients, which requires companion diagnostic testing. Slow adoption of Guardant360 CDx or payer resistance to reimbursement could limit addressable patient uptake and compress early revenue.
- Cash runway and dilution - free cash flow is negative (-$256.9M) and cash on hand is modest (~$48M). If launch costs and ongoing R&D exceed expectations, Arvinas may need to raise capital, diluting shareholders and pressuring the share price.
- Competition and market dynamics - the ESR1-mutated metastatic breast cancer market is evolving quickly (projected to grow), and other oral SERDs and targeted agents could limit VEPPANU's share or force discounts.
- Clinical/regulatory setbacks - downstream safety signals or disappointing Phase 1b/2 data for ARV-102 would materially re-rate the stock lower.
Counterargument
Critics will point out that the biggest positive has already occurred - FDA approval. The market may have already priced some of the upside tied to VEPPANU and the stock remains cheap for a reason: cash burn and commercialization uncertainty. Short interest and weak technicals indicate skepticism. If partner choice and early revenue come in below expectations, the stock can easily test and breach the $5.50 stop level. That is why this is a high-risk, high-reward trade and why position sizing matters.
What would change my mind
I would reduce conviction or move to neutral if any of the following occur: a commercialization partner with limited commercial capability is chosen, early launch metrics show poor diagnostic or prescribing uptake, ARV-102 fails to move forward into planned registrational studies, or the company announces a dilutive financing on unfavorable terms. Conversely, I'll upgrade conviction if Arvinas announces a strong commercial partner, initial revenue beats materially clear operating guidance, or ARV-102 posts robust clinical activity that expands the program's potential.
Conclusion
Arvinas offers a classic asymmetric biotech trade: a newly commercialized, first-in-class product plus an advancing neurology program at a valuation that still reflects substantial execution risk. With an entry at $7.09, stop at $5.50, and a target of $13.50 over a long-term horizon (180 trading days), this Buy is a position-sized, catalyst-driven trade aimed at capturing the re-rating that should accompany successful partner selection and early launch execution. Treat the position as high risk, trade size accordingly, and watch partner, launch, and ARV-102 milestones closely.
Key dates to track
- 05/01/2026 - FDA approval of VEPPANU
- 05/12/2026 - Q1 2026 financial results and related commentary
- H2 2026 - Planned initiation of Phase 1b/Phase 2 registrational activities for ARV-102 (planned)
Trade plan recap: Buy $7.09 / Stop $5.50 / Target $13.50 - long term (180 trading days). Manage size tightly; be ready to trim into positive partner or launch news and protect capital if commercialization dynamics deteriorate.